Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:41:29 ON 02 OCT 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:41:45 ON 02 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2007 HIGHEST RN 948988-82-7
DICTIONARY FILE UPDATES: 1 OCT 2007 HIGHEST RN 948988-82-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10568000\10568000.str

10/568,000 Yong Chu 10-02-2007

$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 24	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8



chain nodes :
6 7 8
ring nodes :
1 2 3 4 5 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

chain bonds :
1-6 3-20 5-14 6-7 6-8 7-9
ring bonds :
1-2 1-5 2-3 3-4 4-5 9-10 9-13 10-11 11-12 12-13 14-15 14-19 15-16 16-17
17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 6-7 6-8 7-9 9-10 9-13 10-11 11-12 12-13
exact bonds :
3-20 5-14
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:42:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 173 TO 747
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:42:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 627 TO ITERATE

100.0% PROCESSED 627 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.01

L3 21 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 12:42:18 ON 02 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Oct 2007 VOL 147 ISS 15
FILE LAST UPDATED: 1 Oct 2007 (20071001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:158826 CAPLUS Full-text
DOCUMENT NUMBER: 142:261392
TITLE: Preparation of pyrrole derivatives as mitotic kinesin inhibitors
INVENTOR(S): Coleman, Paul J.; Cox, Christopher D.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005017190	A2	20050224	WO 2004-US26242	20040811
WO 2005017190	A3	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004264533	A1	20050224	AU 2004-264533	20040811
CA 2534729	A1	20050224	CA 2004-2534729	20040811
EP 1656133	A2	20060517	EP 2004-780997	20040811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1835746	A	20060920	CN 2004-80023308	20040811
JP 2007502775	T	20070215	JP 2006-523386	20040811
US 2006287302	A1	20061221	US 2006-568000	20060210
PRIORITY APPLN. INFO.:			US 2003-495466P	P 20030815
			WO 2004-US26242	W 20040811

Current app

OTHER SOURCE(S): CASREACT 142:261392; MARPAT 142:261392
GI



I

AB Title compds. represented by the formula I [wherein R1, R2 = independently H, (un)substituted (cyclo)alkyl, aryl, heterocyclyl; R3 = H, alkyl(hydroxy), alkenyloxyalkyl, etc.; R4 = independently (carbonyl)(oxy)alkyl, carboxy, OH, etc.; R5 = H, halo, CN, etc.; R10 = F or CH2F; R11, R12 = independently H or CH2F; Rx = absent or oxo; m = 0-2; n = 0-3; and pharmaceutically acceptable salts or stereoisomers thereof] were prepd. as mitotic kinesin inhibitors (no data). For example, I (R1 = R2 = Me, R3 = CH2OH, R4 = 2,4-F2, R5 = R10 = R12 = H, R11 = F, Rx = absent, n = 0) was given in a multi-step synthesis starting from .alpha.-allyl-.alpha.-phenylglycine Et ester. The title compds. and their pharmaceutical compns. are useful as mitotic kinesin inhibitors, esp. KSP kinesin inhibitors, for the treatment of cellular proliferative diseases and disorders assocd. with KSP kinesin activity, such as cancer in mammals (no data).

IT 845893-94-9P 845893-95-0P 845893-99-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of pyrrole derivs. as mitotic kinesin inhibitors)

RN 845893-94-9 CAPLUS

CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-N-[(3R,4R)-4-fluoro-3-pyrrolidinyl]-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845893-95-0 CAPLUS

CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-N-[(3S,4R)-4-fluoro-3-pyrrolidinyl]-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845893-99-4 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-N-[(3S,5S)-5-(fluoromethyl)-3-pyrrolidinyl]-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 845893-96-1P 845893-97-2P 845894-00-0P
845894-01-1P 845894-02-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrole derivs. as mitotic kinesin inhibitors)

RN 845893-96-1 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-N-[(3R,4R)-4-fluoro-1-methyl-3-pyrrolidinyl]-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845893-97-2 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-N-[(3S,4R)-4-fluoro-1-methyl-3-pyrrolidinyl]-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845894-00-0 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-N-[(3S,5S)-5-(fluoromethyl)-1-methyl-3-pyrrolidinyl]-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845894-01-1 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-N-[(3S,5R)-5-(fluoromethyl)-1-methyl-3-pyrrolidinyl]-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845894-02-2 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-N-[(3S,5R)-5-(fluoromethyl)-3-pyrrolidinyl]-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 845893-98-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrrole derivs. as mitotic kinesin inhibitors)
RN 845893-98-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-[[[(2S)-4-(2,5-difluorophenyl)-2,5-dihydro-2-(hydroxymethyl)-2-phenyl-1H-pyrrol-1-yl]carbonyl]amino]-2-(fluoromethyl)-, 1,1-dimethylethyl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



ODP. / 102(e).

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:368866 CAPLUS Full-text
DOCUMENT NUMBER: 140:391193
TITLE: Preparation of dihydropyrroles as mitotic kinesin inhibitors for treating cellular proliferative diseases
INVENTOR(S): Breslin, Michael J.; Coleman, Paul J.; Cox, Christopher D.; Hartman, George D.; Mariano, Brenda J.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037171	A2	20040506	WO 2003-US32405	20031014
WO 2004037171	A3	20040708		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2500848	A1	20040506	CA 2003-2500848	20031014
AU 2003287057	A1	20040513	AU 2003-287057	20031014
EP 1556052	A2	20050727	EP 2003-777578	20031014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006506456	T	20060223	JP 2005-501618	20031014
US 2006100191	A1	20060511	US 2005-531495	20050415
US 7235580	B2	20070626		

PRIORITY APPLN. INFO.: US 2002-419570P P 20021018
US 2003-479712P P 20030619
WO 2003-US32405 W 20031014

OTHER SOURCE(S): MARPAT 140:391193

GI



I



II

AB Title compds. I [wherein R1 = (un)substituted acyl(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), aryl, heterocyclyl, alkyl, etc.; R2 and R6 = independently (un)substituted aryl(alkyl), cycloalkyl, or heterocyclyl; R3 = (un)substituted alkoxyalk(en/yn)yl, carbamoylalk(en/yn)yl, alkylsulfonylalk(en/yn)yl, etc.; R4, R5, and R7 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, perfluoroalkyl, arylalkyl, or heterocyclyl; or R5 and R7 are combined to form an oxo or sulfoxo; or pharmaceutically acceptable salt of stereoisomer thereof] were prepd. for treating cellular proliferative diseases, for treating disorders assocd. with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compns. which comprise these compds., and methods of using them to treat cancer (no data). For instance, palladium catalyzed Suzuki coupling of 7a-phenyldihydro-1H-pyrrolo[1,2-c][1,3]oxazole-3,6(5H)-dione (multi-step prepn. given) and 2,5-difluorophenylboronic acid afforded 6-(2,5-difluorophenyl)-7a-phenyl-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol- 3-one. The pyrrolooxazolone was treated with NaOH in EtOH to give the (hydroxymethyl)pyrrole, which was O-protected with tert-butyldimethylsilyl chloride. Reaction of the pyrrole with triphosgene and dimethylamine, followed by deprotection using triethylamine trihydrofluoride in MeCN provided II. In a kinesin ATPase assay using a human KSP motor domain construct and microtubules from bovine brain tubulin, example compds. inhibited the ATPase hydrolysis reaction with IC50 .ltoreq. 50 .mu.M.

IT 686320-55-8P, [4-(2,5-Difluorophenyl)-2-phenyl-1-[[(1-methylpyrrolidin-3-yl)(methyl)amino]carbonyl]-2,5-dihydro-1H-pyrrol-2-yl]methanol 686320-56-9P, [4-(2,5-Difluorophenyl)-2-phenyl-1-[[(1-benzylpyrrolidin-3-yl)(methyl)amino]carbonyl]-2,5-dihydro-1H-pyrrol-2-

yl]methanol 686320-57-0P, [4-(2,5-Difluorophenyl)-2-phenyl-1-[[(pyrrolidin-3-yl)(methyl)amino]carbonyl]-2,5-dihydro-1H-pyrrol-2-yl]methanol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(KSP inhibitor; prepn. of dihydropyrroles as KSP inhibitors for treating proliferative diseases)

RN 686320-55-8 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-2-(hydroxymethyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)-2-phenyl- (CA INDEX NAME)



RN 686320-56-9 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (CA INDEX NAME)



RN 686320-57-0 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-2-(hydroxymethyl)-N-methyl-2-phenyl-N-3-pyrrolidinyl- (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:1006780 CAPLUS Full-text
DOCUMENT NUMBER: 140:77020

TITLE: Preparation of pyrrole derivatives as mitotic kinesin inhibitors

INVENTOR(S): Arrington, Kenneth L.; Coleman, Paul J.; Cox, Christopher D.; Fraley, Mark E.; Garbaccio, Robert M.; Hartman, George D.; Hoffman, William F.; Tasber, Edward S.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 401 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105855	A1	20031224	WO 2003-US18482	20030612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487489	A1	20031224	CA 2003-2487489	20030612
AU 2003245453	A1	20031231	AU 2003-245453	20030612
BR 2003011784	A	20050308	BR 2003-11784	20030612
EP 1515724	A1	20050323	EP 2003-739093	20030612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1674906	A	20050928	CN 2003-819318	20030612
JP 2005536479	T	20051202	JP 2004-512758	20030612
ZA 2004009334	A	20060222	ZA 2004-9334	20041119
US 2006105997	A1	20060518	US 2004-517559	20041208
IN 2004CN02798	A	20060210	IN 2004-CN2798	20041210
MX 2004PA12642	A	20050323	MX 2004-PA12642	20041213
NO 2005000198	A	20050311	NO 2005-198	20050113

PRIORITY APPLN. INFO.:	US 2002-388621P	P	20020614
	US 2002-403830P	P	20020815
	US 2002-426940P	P	20021115
	US 2003-458318P	P	20030328
	WO 2003-US18482	W	20030612

OTHER SOURCE(S): MARPAT 140:77020

GI



I



II

AB The invention relates to dihydropyrrole compds. that are useful for treating cellular proliferative diseases and disorders assocd. with KSP kinesin activity. The invention also relates to compns. which comprise these compds. and methods of using them to treat cancer in mammals. Compds. I [R1 is (C1-C6-alkylene)n-X-R, (n is 0 or 1; X is CO, SO2, NH, PO, etc.; R is alkyl, aryl, amino group, etc.), aryl, heterocyclyl, or alkyl; R2, R6 are aryl, aralkyl, cycloalkyl, or heterocyclyl; R3-R5, R7-R9 are H, alk(en)(yn)yl, aryl, aralkyl, heterocyclyl, etc.] (including amino acid derivs.) are claimed. For example, a detailed synthesis for the prepn. of II is outlined, which includes reaction of 2 chloro-5-fluorobenzenediazonium tetrafluoroborate with Boc-protected 2,5-dihydro-1H-pyrrole-1-carboxylate.

IT 639075-03-9P 639075-04-0P 639075-07-3P
639075-08-4P 639075-09-5P 639075-10-8P
639075-11-9P 639075-12-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrole derivs. as mitotic kinesin inhibitors)

RN 639075-03-9 CAPLUS

CN 1H-Pyrrole-1-carboxamide, 4-(5-chloro-2-fluorophenyl)-2,5-dihydro-N-methyl-2-phenyl-N-(3R)-3-pyrrolidinyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639075-04-0 CAPLUS

CN 1H-Pyrrole-1-carboxamide, 4-(5-chloro-2-fluorophenyl)-2,5-dihydro-N-methyl-2-phenyl-N-(3R)-3-pyrrolidinyl-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 639075-03-9
CMF C22 H23 Cl F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 639075-07-3 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(5-chloro-2-fluorophenyl)-2,5-dihydro-N-methyl-2-phenyl-N-(3S)-3-pyrrolidinyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639075-08-4 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(5-chloro-2-fluorophenyl)-2,5-dihydro-N-methyl-2-phenyl-N-(3S)-3-pyrrolidinyl-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 639075-07-3
CMF C22 H23 Cl F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 639075-09-5 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-N-methyl-2-phenyl-N-3-pyrrolidinyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639075-10-8 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-N-methyl-2-phenyl-N-3-pyrrolidinyl-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 639075-09-5
CMF C22 H23 F2 N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 639075-11-9 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-N-methyl-N-[(3R)-1-methyl-3-pyrrolidinyl]-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639075-12-0 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-N-methyl-N-[(3S)-1-methyl-3-pyrrolidinyl]-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 639075-02-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrrole derivs. as mitotic kinesin inhibitors)
RN 639075-02-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[(2S)-4-(5-chloro-2-fluorophenyl)-2,5-dihydro-2-phenyl-1H-pyrrol-1-yl]carbonyl]methylamino]-, phenylmethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.16	190.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

STN INTERNATIONAL LOGOFF AT 12:45:20 ON 02 OCT 2007